Screening and surveillance of oesophageal varices in patients with HCV-positive liver cirrhosis successfully treated by direct-acting antiviral agents.
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
revised:
10
01
2022
received:
17
09
2021
accepted:
07
02
2022
pubmed:
28
2
2022
medline:
26
4
2022
entrez:
27
2
2022
Statut:
ppublish
Résumé
limited evidence is available to guide hepatologists regarding endoscopic surveillance of oesophageal varices (EV) in Hepatitis C Virus (HCV)-positive cirrhotic patients achieving a sustained virologic response. To address these issues, we conducted a long-term prospective study on 427 HCV-positive cirrhotic patients successfully treated by Direct Antiviral Agents (DAAs). Patients were divided into two groups according to their baseline Baveno VI status: Group 1 (92, 21.5%, favourable Baveno VI status) and Group 2 (335, 78.5%, unfavourable Baveno VI status). Each patient underwent baseline endoscopy and was endoscopically monitored for a median follow-up of 65.2 months according to Baveno VI recommendations. About 4.3% of Group 1 patients showed baseline EV compared with 30.1% of Group 2 patients (p < .0001). No patients belonging to Group 1 without baseline EV developed EV at follow-up endoscopy compared with 6.5% in Group 2 patients (p = .02); 69/107 (64.5%) patients with baseline EV showed small varices. During the endoscopic follow-up, EV disappeared/improved in 36 (33.6%), were stable in 39 (36.4%) and worsened in 32 (29.9%) patients, all belonging to Group 2 (p = .001). Improvement in Baveno VI status was observed in 118/335 (35.2%, p < .0001) of Group 2 patients and among those without pre-therapy EV, none developed EV throughout the follow-up. HCV-positive cirrhotic patients cured by DAAs showing baseline favourable Baveno VI status and no worsening during follow-up can safely avoid endoscopic screening and surveillance. Patients having unfavourable Baveno VI status without baseline EV who improve their status may suspend further endoscopic surveillance.
Sections du résumé
BACKGROUND & AIMS
limited evidence is available to guide hepatologists regarding endoscopic surveillance of oesophageal varices (EV) in Hepatitis C Virus (HCV)-positive cirrhotic patients achieving a sustained virologic response. To address these issues, we conducted a long-term prospective study on 427 HCV-positive cirrhotic patients successfully treated by Direct Antiviral Agents (DAAs).
METHODS
Patients were divided into two groups according to their baseline Baveno VI status: Group 1 (92, 21.5%, favourable Baveno VI status) and Group 2 (335, 78.5%, unfavourable Baveno VI status). Each patient underwent baseline endoscopy and was endoscopically monitored for a median follow-up of 65.2 months according to Baveno VI recommendations.
RESULTS
About 4.3% of Group 1 patients showed baseline EV compared with 30.1% of Group 2 patients (p < .0001). No patients belonging to Group 1 without baseline EV developed EV at follow-up endoscopy compared with 6.5% in Group 2 patients (p = .02); 69/107 (64.5%) patients with baseline EV showed small varices. During the endoscopic follow-up, EV disappeared/improved in 36 (33.6%), were stable in 39 (36.4%) and worsened in 32 (29.9%) patients, all belonging to Group 2 (p = .001). Improvement in Baveno VI status was observed in 118/335 (35.2%, p < .0001) of Group 2 patients and among those without pre-therapy EV, none developed EV throughout the follow-up.
CONCLUSIONS
HCV-positive cirrhotic patients cured by DAAs showing baseline favourable Baveno VI status and no worsening during follow-up can safely avoid endoscopic screening and surveillance. Patients having unfavourable Baveno VI status without baseline EV who improve their status may suspend further endoscopic surveillance.
Identifiants
pubmed: 35220668
doi: 10.1111/liv.15210
pmc: PMC9311418
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1121-1131Informations de copyright
© 2022 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
J Hepatol. 2020 Dec;73(6):1415-1424
pubmed: 32535060
Hepatology. 2017 Jan;65(1):310-335
pubmed: 27786365
Hepatology. 2020 Mar;71(3):1023-1036
pubmed: 31365764
J Hepatol. 2020 Mar;72(3):472-480
pubmed: 31629779
Eur J Clin Invest. 2020 May;50(5):e13231
pubmed: 32291753
Hepatology. 2017 Dec;66(6):1980-1988
pubmed: 28696510
Liver Int. 2017 May;37(5):707-716
pubmed: 27862856
J Hepatol. 2015 Jul;63(1):199-236
pubmed: 25911336
J Viral Hepat. 2017 Oct;24(10):823-831
pubmed: 28295923
Hepatology. 2021 Apr;73(4):1275-1289
pubmed: 32659847
J Hepatol. 2015 Sep;63(3):743-52
pubmed: 26047908
J Gastroenterol. 2020 Feb;55(2):205-216
pubmed: 31493238
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1744-1755.e11
pubmed: 31077823
Gastroenterology. 2019 Mar;156(4):997-1009.e5
pubmed: 30768988
Gastroenterology. 2017 May;152(6):1578-1587
pubmed: 28344022
Liver Int. 2018 Aug;38(8):1442-1448
pubmed: 29495113
Gastroenterology. 2019 Mar;156(4):864-866
pubmed: 30776346
Aliment Pharmacol Ther. 2020 Feb;51(3):364-373
pubmed: 31773763
Clin Liver Dis. 2021 May;25(2):253-289
pubmed: 33838850
J Hepatol. 2016 Nov;65(5):899-905
pubmed: 27388923
Clin Infect Dis. 2020 Dec 17;71(10):2726-2729
pubmed: 32386053
Liver Int. 2022 May;42(5):1121-1131
pubmed: 35220668
Aliment Pharmacol Ther. 2017 Jan;45(1):139-149
pubmed: 27910154
Gastrointest Endosc. 1981 Nov;27(4):213-8
pubmed: 6975734
Gastroenterology. 2017 Jan;152(1):142-156.e2
pubmed: 27641509